Lifestyle

'NexPowder' and 'NexSphere F' Soar… NextBio Posts Record-High Third-Quarter Earnings

YU JIN-HEE
2026-11-17 15:32:02

[Edaily Reporter YU JIN-HEE ] #NEXTBIOMEDICAL CO., LTD. has once again set a new record for its highest-ever quarterly revenue, driven by the global success of its flagship product line. The company is credited with achieving two goals simultaneously—revenue growth and improved profitability—while continuing its aggressive research and development (R&D) investments and significantly reducing its operating loss.

NEXTBIOMEDICAL CO., LTD. announced in a regulatory filing on the 16th that its revenue for the third quarter of 2026 reached approximately 5.2 billion won, an increase of about 6% from the previous quarter. With this, the company has once again set a new record for quarterly revenue, and its cumulative revenue for the first three quarters totaled approximately 14.3 billion won.

(Photo: NEXTBIOMEDICAL CO., LTD.)


Profitability metrics also showed a clear trend of recovery. The operating loss for the third quarter was approximately 870 million won, representing a reduction of about 16% in the loss compared to the previous quarter. During the same period, the net loss totaled approximately 3.5 billion won.

These strong results stem from a combination of robust overseas sales of the endoscopic hemostatic agent “Nexpowder™” and the rapid growth of “Nexsphere-F™,” an embolization agent that serves as a next-generation growth driver.

Cumulative sales of Nexpowder™ for the first three quarters of this year reached approximately 11.9 billion won, an increase of about 10% compared to the same period last year. Notably, exports accounted for approximately 97% of total sales, solidifying the company’s position in the global market. By region, the export breakdown was as follows: △U.S. 51% △Europe 42% △Japan 7%, maintaining a stable sales base centered on SUNJIN Co., Ltd.’s advanced healthcare markets.

The strong performance of the embolization product line was also notable. Cumulative third-quarter revenue from embolization products, including NexSphere and NexSphere-F, reached approximately 2.2 billion won—a sharp increase of about 25% compared to the same period last year—establishing this segment as a new core growth driver for the company.

The company also continued its aggressive R&D investment strategy to fuel future growth. Selling, general, and administrative expenses (SG&A) for the third quarter totaled approximately 4.3 billion won, a 34% increase year-over-year. This reflects the company’s focus on R&D for key pipeline products, such as clinical trials for NexSphere-F’s U.S. Food and Drug Administration (FDA) approval. In fact, ordinary R&D expenses for the third quarter amounted to approximately 2.6 billion won, accounting for about 50% of total revenue. It is encouraging that, despite the large-scale R&D expenditures, the operating loss narrowed thanks to revenue growth.

NEXTBIOMEDICAL CO., LTD. plans to continue accelerating efforts to expand NexPowder’s global market share and strengthen the competitiveness of its embolization products. In particular, the company intends to complete the clinical trials and regulatory approval process for NexSphere-F without delay and to solidify its foundation for mid- to long-term growth by expanding its overseas presence through global partnerships.

NEXTBIOMEDICAL CO., LTD. official stated, “In the third quarter, we once again set a new record for quarterly revenue, driven by stable global sales of NexPowder and the rapid growth of our embolization products,” adding, “We will continue to expand the overseas market for our flagship products and pursue research, development, and clinical trials for next-generation products to enhance our competitiveness in the global medical device market.”

Economy

Corporation

IT·Science

Economy

[Exclusive] ‘SSD Generational Shift’… SK Hynix Supplies Customer Samples of 122TB 5th-Generation eSSD

SK hynix has developed a 122-terabyte (TB) ultra-high-capacity solid-state drive (SSD) for use in artificial intelligence (AI) data centers and has begun supplying samples to customers. Amid growing d…
2026-11-17 15:31:58

Corporation

SANIGEN Co., Ltd. Launches Human Molecular Diagnostics Business in Earnest… "Commercialization of Highly Sensitive, Rapid Dengue Fever Diagnostic Kit"

#SANIGEN Co., Ltd., a molecular diagnostics company specializing in microorganisms, has filed a patent for proprietary technology capable of detecting the dengue virus in just one hour, marking the of…
2026-11-17 15:36:02

IT·Science

U.S. Blocks China’s Indirect Use of Overseas AI Chips… Could This Be an Opportunity for South Korea’s SKT AIDC?

With the U.S. government introducing export control regulations that block Chinese companies from accessing overseas data centers via workarounds, changes are expected in the global competition to att…
2026-11-17 15:43:06